Intrinsiqq
Bio Essence Corp logo

Bio Essence Corp Quality Score

BIOE

⊜ Compare
Quality80

Growth remains strong (avg 100/100), but business quality is pulling the composite down (avg 60/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
10.9x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
80/100
23.5x

20–25x, moderate cash flow premium

Revenue Growth
100/100
47.1%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
31.3%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
63.0%

Heavy dilution above 5%

Margin Trend
100/100
+135.1pp

Expanded 3+pp, strong improvement

Capital Structure
40/100
$2M

Net debt/FCF of 1.4x, somewhat elevated

2022
$6262
$1.00M
2023
$114
$1.00M
2024
$1371
$2.00M
TTM
$675
$2.00M
CashDebt
Return on Capital
100/100
56.7%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

Bio Essence (BIOE) quality: score, margins and returns

Bio Essence (BIOE) scores 80/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 52.9% operating margins and 56.7% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Bio Essence (BIOE) a high-quality business?+

Bio Essence scores 80 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 52.9% operating margin and a 56.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Bio Essence's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BIOE's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Bio Essence scores well and where it falls behind.

What is Bio Essence's return on invested capital (ROIC)?+

Bio Essence earns about 56.7% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BIOE's margins and growth on this scorecard to judge durability.

How profitable is Bio Essence?+

Bio Essence runs an operating margin of about 52.9% and a net margin of about 52.1%. Revenue has grown at roughly 14.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BIOE

CompareIntrinsic value
CNTBConnect Biopharma Holdings Ltd.
$0.78+0.90%10
TRAWTraws Pharma Inc.
$0.27-10.00%40
UPBUpstream Bio, Inc.
$3.70+9.14%21
PMHSPolomar Health Services Inc.
$0.19+0.00%40
XBIOXenetic Biosciences Inc.
$2.01-3.37%40
TXMDTherapeuticsMD, Inc.
$1.82+2.25%25
VTGNVistaGen Therapeutics Inc.
$0.18+5.88%10
CLSDQClearside Biomedical, Inc.
No recent price10

Spot a number that looks wrong? Check it in BIOE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BIOE

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.